The Dangerous Link Between COVID-19 and Pulmonary Embolism You Shouldn’t Ignore

At the height of the pandemic, most people feared COVID-19 for what it did to the lungs. But what surprised many doctors was something deeper and more dangerous happening inside the bloodstream. COVID-19 is not just a respiratory illness. It can trigger abnormal blood clotting, increasing the risk of life-threatening conditions like pulmonary embolism.

Studies have shown that up to 20-30% of hospitalized COVID-19 patients developed blood clots, even while receiving preventive care. In severe cases, these clots travel to the lungs, blocking critical arteries and cutting off oxygen supply.

This is known as a pulmonary embolism, a condition that can escalate rapidly and become fatal without warning. What makes it even more concerning is that these clots can form during infection or even weeks after recovery, when many believe the danger has already passed.

The connection between COVID-19 and clotting lies in how the virus affects the body. It can damage blood vessels, trigger inflammation, and disrupt normal clotting mechanisms, creating the perfect conditions for clots to form silently. For some, the first sign is sudden shortness of breath or chest pain. For others, there may be no warning at all until the situation becomes critical.

This is why understanding the link matters. COVID-19 may come and go, but its effects can linger in ways many people do not expect. In the sections ahead, you’ll discover the connection between Covid-19 and pulmonary embolism, the warning signs to watch for, and what steps can help protect your health.

The Link Between COVID-19 and Pulmonary Embolism

The primary mechanism linking COVID-19 to an increased risk of pulmonary blood clots is a complex interplay of direct viral-induced endothelial cell injury, a massive, dysregulated inflammatory response (cytokine storm), and subsequent activation of the coagulation cascade.

This multi-pronged attack on the body’s vascular system disrupts the delicate balance between clotting and bleeding, tipping the scales heavily toward thrombosis, a condition known as COVID-19-associated coagulopathy (CAC). The SARS-CoV-2 virus doesn’t just damage the lungs; it wages a systemic assault on the circulatory system, making the formation of dangerous clots a hallmark of severe disease.

This process is often explained by Virchow’s triad, a century-old principle that identifies three broad factors contributing to thrombosis: endothelial injury, abnormal blood flow (stasis), and hypercoagulability. COVID-19 profoundly impacts all three components.

What is a Pulmonary Embolism and Its Danger

A pulmonary embolism (PE) is a life-threatening condition that occurs when a blood clot, typically formed in a deep vein in the leg (deep vein thrombosis or DVT), breaks free, travels through the bloodstream, and becomes lodged in one of the pulmonary arteries in the lungs. This blockage obstructs blood flow to a portion of the lung tissue, leading to a cascade of dangerous physiological consequences.

The primary danger of a PE lies in its ability to cause severe strain on the heart and drastically reduce the body’s oxygen levels. The consequences of a pulmonary embolism are severe and can be fatal if not treated immediately.

• Restricted Blood Flow and Lung Tissue Damage: When an artery is blocked, the lung tissue it supplies cannot receive oxygen-rich blood and can begin to die, a condition called pulmonary infarction. This not only impairs the lung’s primary function of gas exchange but can also lead to inflammation and fluid buildup in the lungs.
• Decreased Blood Oxygen Levels (Hypoxemia): With blood flow to parts of the lungs obstructed, the body’s ability to oxygenate the blood is severely compromised. This leads to low oxygen levels throughout the body, which can damage vital organs, including the brain and heart, and cause symptoms like severe shortness of breath, confusion, and cyanosis (a bluish tint to the skin).
• Increased Strain on the Heart: The right ventricle of the heart is responsible for pumping blood into the pulmonary arteries. When these arteries are blocked by a clot, the pressure within them rises dramatically (pulmonary hypertension). The right ventricle must work much harder to push blood past the obstruction. This acute and immense strain can cause the right ventricle to weaken, dilate, and ultimately fail, a condition known as acute right heart failure, which is a leading cause of death from PE. In severe cases, this can lead to obstructive shock and cardiac arrest.

Ways SARS-CoV-2 Virus Promotes Blood Clot Formation

The SARS-CoV-2 virus promotes blood clot formation through three interconnected pathways: it directly attacks and damages the endothelial cells lining blood vessels, it triggers an overactive immune response that causes systemic inflammation, and it directly activates platelets and other components of the clotting system. This combination creates a uniquely prothrombotic environment throughout the body.

1. Direct Damage to the Endothelium

The SARS-CoV-2 virus enters human cells by binding to the ACE2 receptor, which is abundantly present on endothelial cells, the single layer of cells that form the inner lining of all blood vessels. When the virus infects these cells, it causes direct injury and cell death (apoptosis). A healthy endothelium is smooth and produces substances that prevent clotting.

A damaged endothelium, however, becomes a potent trigger for coagulation. It exposes underlying tissue factor and collagen, which immediately initiates the clotting cascade, and it loses its ability to regulate local blood flow and prevent platelet aggregation. This widespread endothelial dysfunction, or endotheliitis, is a core feature of severe COVID-19.

2. Overactive Immune Response (Cytokine Storm)

In severe cases, COVID-19 infection leads to a hyperinflammatory state known as a cytokine storm, where the immune system releases an overwhelming flood of inflammatory signaling molecules (cytokines like IL-6 and TNF-α). This systemic inflammation further damages the endothelium, making blood vessels leaky and more prone to clotting.

These cytokines also directly stimulate the liver to produce more pro-coagulant factors, such as fibrinogen, and activate immune cells like neutrophils, which can release neutrophil extracellular traps (NETs) – web-like structures of DNA and proteins that trap pathogens but also provide a scaffold for thrombus formation.

3. Activation of Platelets and Clotting Factors

Both the direct viral infection and the inflammatory cytokines can directly activate platelets, the small cell fragments responsible for forming initial plugs at sites of injury. In COVID-19, platelets become hyperactive, meaning they are stickier and more likely to aggregate into clumps, forming microthrombi (tiny clots) in small vessels, particularly in the lungs and other organs.

Furthermore, the inflammatory state activates the entire coagulation cascade, leading to the excessive generation of thrombin, the key enzyme that converts fibrinogen into fibrin, the protein mesh that forms the structural backbone of a stable blood clot.

The Risk of Blood Clots Higher with COVID-19 Compared to Other Viral Infections

Yes, the risk of developing both venous and arterial blood clots is significantly and consistently higher with COVID-19 compared to other severe viral respiratory infections, including influenza.

While any severe illness that requires hospitalization and causes immobility can increase the risk of thrombosis, the magnitude and mechanisms of clot formation in COVID-19 appear to be unique and far more pronounced. This has been a consistent finding in numerous large-scale studies since the beginning of the pandemic.

• Higher Incidence Rates: Studies published in journals like The Lancet and the BMJ have compared large cohorts of hospitalized patients with COVID-19 and influenza. These analyses consistently show that the incidence of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is several-fold higher in patients with COVID-19. For critically ill patients in the ICU, the rates of thrombotic complications have been reported to be as high as 30-40% in some COVID-19 cohorts, a figure substantially greater than that seen in ICU patients with influenza or other forms of acute respiratory distress syndrome (ARDS).
• Different Clotting Profiles: The nature of the clotting in COVID-19 also appears distinct. Beyond the typical VTE, COVID-19 is associated with a high rate of immunothrombosis, where inflammation and coagulation are pathologically linked. This leads to the formation of microthrombi within the small blood vessels of the lungs and other organs, a phenomenon less commonly observed with influenza. Furthermore, COVID-19 has been linked to an increased risk of arterial clots, leading to strokes and heart attacks, at a higher rate than influenza.
• Unique Pathophysiological Drivers: The primary reason for this difference lies in the specific pathophysiology of SARS-CoV-2. As mentioned, its ability to directly infect and cause widespread damage to the endothelium via the ACE2 receptor is a key differentiator. While influenza can cause systemic inflammation, it does not typically induce the same degree of severe, systemic endotheliitis. The resulting combination of direct endothelial injury, the intense cytokine storm, and platelet hyperactivation in COVID-19 creates a uniquely potent prothrombotic state that surpasses what is typically seen with other viral pathogens.

Symptoms of Pulmonary Blood Clots Following a COVID-19 Infection

Common Warning Signs of a Pulmonary Embolism

The most common warning signs of a pulmonary embolism are dominated by a sudden and dramatic change in respiratory and cardiovascular status, including abrupt shortness of breath, severe chest pain, and a rapid heart rate. These classic symptoms should never be ignored, especially in someone recovering from or currently battling COVID-19.

• Sudden Shortness of Breath (Dyspnea): This is the most frequent symptom. Unlike the gradual breathlessness that can accompany a lung infection, the dyspnea from a PE typically appears suddenly and without an obvious cause. It can occur while at rest or during minimal physical activity and often feels disproportionate to the level of exertion. The individual may feel like they cannot get enough air in, no matter how deeply they breathe.
• Sharp Chest Pain (Pleuritic Pain): This is another hallmark sign. The pain is often described as sharp, stabbing, or knife-like and is located on one side of the chest. A key feature is that the pain significantly worsens upon taking a deep breath (inspiration), coughing, sneezing, or even moving the upper body. This type of pain is caused by inflammation of the pleura, the lining of the lungs, which becomes irritated by the nearby blood clot and lack of blood flow.
• Rapid or Irregular Heartbeat (Tachycardia/Palpitations): The heart attempts to compensate for the reduced oxygen levels and the blockage in the pulmonary arteries by beating faster. An individual may feel their heart is racing, pounding, or fluttering. A sustained heart rate of over 100 beats per minute at rest is a significant warning sign.
• Coughing Up Blood (Hemoptysis): While less common than the other symptoms, coughing up blood or blood-streaked mucus is a very serious indicator of a PE. It suggests that the lack of blood flow has led to damage (infarction) of the lung tissue.
• Dizziness, Lightheadedness, or Fainting (Syncope): These symptoms can occur if the clot is large and significantly obstructs blood flow, leading to a drop in blood pressure and reduced oxygen supply to the brain. Fainting in the context of other PE symptoms is a sign of a massive, life-threatening embolism.

Blood Clot Symptoms vs. COVID-19 Recovery Symptoms

The symptoms of a pulmonary blood clot can easily be mistaken for common COVID-19 recovery symptoms, creating a dangerous potential for delayed diagnosis and treatment.

This overlap is one of the most significant challenges in post-infection care. Many individuals recovering from COVID-19, particularly moderate to severe cases, experience lingering issues that mirror the warning signs of a PE, making it difficult to distinguish between normal recovery and a medical emergency without a clinical evaluation.

1. Overlapping Symptoms

The most prominent overlapping symptoms are shortness of breath (dyspnea) and fatigue. Post-COVID syndrome, or Long COVID, frequently involves persistent breathlessness, especially with exertion, as the lungs heal. Similarly, profound fatigue and a general feeling of malaise are hallmarks of both conditions.

A persistent cough can also be present during COVID recovery. If an individual is already experiencing these symptoms, they might dismiss the new or worsening signs of a PE as just part of their ongoing recovery process.

2. Key Differentiating Factors

Despite the overlap, there are critical differences to watch for. The most important differentiator is the onset and character of the symptoms.

• Sudden Onset: While post-COVID breathlessness may be chronic or worsen gradually with activity, the shortness of breath from a PE is typically very sudden and can occur even at rest. A patient might go from feeling relatively stable to being acutely breathless in a matter of minutes.
• Pleuritic Chest Pain: The sharp, stabbing chest pain that worsens with a deep breath is highly characteristic of a PE and is not a typical feature of COVID-19 recovery. While COVID-19 can cause chest pain, it is often described as a dull ache or tightness, whereas PE pain is distinctly sharp and pleuritic.
• Unilateral Leg Swelling: The presence of swelling, pain, tenderness, and redness in one leg is a classic sign of a deep vein thrombosis (DVT), the precursor to most pulmonary embolisms. This symptom is entirely unrelated to COVID-19 recovery and is a major red flag that the other respiratory symptoms could be due to a PE.

Risk Factors for Developing Pulmonary Blood Clots from COVID-19

The primary risk factors for developing pulmonary blood clots from COVID-19 include the severity of the infection, hospitalization (particularly ICU admission), older age, personal or family history of blood clots, and the presence of pre-existing medical conditions.

To begin, it’s clear that the more severe the body’s inflammatory response to the virus, the higher the risk of thrombotic complications.

Patients who require hospitalization are at substantially higher risk than those with mild, outpatient cases, not only because their illness is more severe but also due to prolonged immobility, which is an independent and powerful risk factor for clot formation. Other significant contributors include obesity, active cancer, recent surgery or trauma, and underlying cardiovascular diseases like hypertension and heart failure.

Groups At Risk for COVID-19-associated Blood Clots

The individuals considered most at risk for COVID-19-associated blood clots are patients with severe or critical disease requiring hospitalization, especially those admitted to the intensive care unit (ICU), older adults, and those with specific pre-existing health conditions. This high-risk profile is shaped by the convergence of intense inflammation, immobility, and underlying vascular vulnerability.

• Patients with Severe COVID-19: This is the single greatest risk factor. Individuals who develop pneumonia, acute respiratory distress syndrome (ARDS), or require supplemental oxygen or mechanical ventilation experience the most extreme levels of systemic inflammation (cytokine storm) and endothelial damage. The inflammatory markers in these patients, such as C-reactive protein (CRP) and D-dimer (a small protein fragment present in the blood after a clot is degraded), are often highly elevated, directly correlating with a prothrombotic state. Prolonged immobility from being bedridden in a hospital or ICU setting further exacerbates this risk by causing blood to pool in the deep veins of the legs.
• Older Adults: Advanced age (typically defined as over 60 or 65 years) is an independent risk factor for venous thromboembolism (VTE). Older individuals often have less resilient vascular systems, a higher baseline level of inflammation, and are more likely to have other co-morbidities. Their response to COVID-19 is often more severe, and they are more prone to prolonged periods of immobility during illness, all of which compound to significantly elevate their risk of clotting.
• Individuals with Pre-existing Conditions: Several underlying health issues dramatically increase the likelihood of developing a blood clot during a COVID-19 infection. These include:
  • Obesity: Adipose (fat) tissue is known to be a source of chronic, low-grade inflammation and pro-thrombotic factors.
  • Cardiovascular Diseases: Conditions like hypertension, coronary artery disease, and heart failure mean the vascular system is already compromised and more susceptible to the damage caused by the virus and inflammation.
  • Cancer: Active cancer is a well-known hypercoagulable state, and when combined with a severe infection like COVID-19, the risk becomes extremely high.
  • Prior History of Blood Clots: Anyone with a personal or family history of DVT or PE has an inherently higher risk of developing a new clot, especially when faced with a major trigger like a severe COVID-19 infection.
  • Diabetes: This condition is associated with endothelial dysfunction and a pro-inflammatory state, adding to the risk.

Long COVID to Long-term Risk of Blood Clots

Emerging evidence strongly suggests that having Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC), can increase the long-term risk of blood clots for months, and potentially more than a year, after the initial infection has resolved. The risk is not confined to the acute phase of the illness. The lingering biological disruptions caused by the virus can maintain a prothrombotic, or hypercoagulable, state long after the patient has tested negative.

Specifically, the mechanisms behind this prolonged risk are under active investigation but are thought to be driven by several factors associated with Long COVID.

• Persistent Inflammation: One of the core features of Long COVID is persistent, low-grade systemic inflammation. The immune system fails to return to a normal baseline, and inflammatory markers can remain elevated for months. This chronic inflammation continues to irritate the endothelial lining of blood vessels, preventing full healing and maintaining a state of endothelial dysfunction that promotes clotting.
• Endothelial Dysfunction: The widespread damage to the endothelium that occurs during the acute infection may not fully resolve in individuals with Long COVID. These blood vessel linings can remain dysfunctional, unable to properly regulate blood flow and prevent inappropriate clotting. This ongoing vascular pathology is a critical driver of long-term thrombotic risk.
• Autoimmunity and Persistent Viral Reservoirs: Some theories suggest that Long COVID may involve an autoimmune component, where the body produces antibodies that mistakenly attack its own cells, including endothelial cells. Others propose that fragments of the virus or its genetic material may persist in certain tissues, acting as a constant trigger for inflammation. Both scenarios could contribute to a sustained prothrombotic environment.
• Clinical Evidence: Large-scale population studies have validated this long-term risk. A notable study published in the BMJ tracked millions of individuals and found that the risk of deep vein thrombosis remained significantly elevated for up to three months post-infection, while the risk of pulmonary embolism was elevated for up to six months. Another study in Circulation showed an increased risk of cardiovascular events, including blood clots, up to a year after the acute infection, even in those who had mild cases. This indicates that the virus’s impact on the vascular system is profound and long-lasting.

Pulmonary Blood Clots Diagnosis In COVID-19 Patients

Diagnosing a pulmonary embolism (PE) in a patient with COVID-19 involves a combination of clinical assessment, blood tests, and advanced imaging, as symptoms like shortness of breath and chest pain can overlap with the viral pneumonia itself.

The initial step often involves a blood test to measure D-dimer levels. D-dimer is a protein fragment produced when a blood clot dissolves in the body. While elevated D-dimer levels are not specific to PE (as inflammation from COVID-19 can also raise them), a normal level can help rule out a clot with a high degree of confidence.

If D-dimer is elevated and clinical suspicion is high, the gold standard for diagnosis is a CT pulmonary angiography (CTPA). This is a specialized type of computed tomography scan where a contrast dye is injected into the veins, allowing radiologists to visualize the pulmonary arteries and identify any blockages or clots with high precision.

In cases where a CTPA is not feasible, a ventilation/perfusion (V/Q) scan may be used as an alternative. This systematic diagnostic pathway is crucial for accurately identifying and treating these life-threatening clots.

• Initial Screening: The D-dimer test serves as a sensitive but non-specific screening tool. In the context of COVID-19, where inflammation is widespread, its primary value is often in its negative predictive power, a normal result makes a significant clot less likely, allowing clinicians to consider other causes for the patient’s symptoms without resorting to more invasive imaging.
• Confirmatory Imaging: The CT pulmonary angiography (CTPA) is the definitive diagnostic test. It provides a detailed, three-dimensional map of the blood vessels in the lungs, clearly showing the location, size, and extent of any emboli, which is critical for determining the severity of the condition and guiding treatment intensity.
• Supportive Assessments: In addition to these primary tests, doctors may use an electrocardiogram (ECG) to check for signs of heart strain caused by the PE, as well as an echocardiogram (ultrasound of the heart) to assess the function of the right ventricle, which pumps blood to the lungs and can become enlarged and strained by a large clot.

Consequences of Surviving a COVID-19-related Pulmonary Embolism

The journey to recovery often extends far beyond the initial hospital stay, with many individuals facing long-term health consequences that can impact their quality of life.

One of the most common issues is post-PE syndrome, a condition characterized by persistent symptoms such as shortness of breath, especially with exertion, chronic chest discomfort, and a reduced capacity for physical activity. These symptoms can linger for months or even years, making it difficult for individuals to return to their previous level of function.

In a more severe but rarer subset of patients, the clots do not fully dissolve. Instead, they organize into fibrous, scar-like tissue within the pulmonary arteries, leading to a serious condition known as Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

This scarring obstructs blood flow, causing dangerously high blood pressure in the lungs and straining the right side of the heart, which can eventually lead to heart failure if left untreated. Many survivors also require long-term management to prevent recurrence. These long-term effects underscore the importance of follow-up care and patient monitoring after a PE diagnosis.

• Ongoing Anticoagulation: To prevent new clots from forming, most survivors will be prescribed anticoagulant therapy (blood thinners) for at least three to six months, and in some cases, indefinitely. This requires regular monitoring and lifestyle adjustments to manage the increased risk of bleeding.
• Functional and Psychological Impact: Beyond the physical symptoms, post-PE syndrome can have a significant psychological toll, leading to anxiety, depression, and a fear of recurrence. Comprehensive recovery often involves cardiac rehabilitation programs designed to slowly and safely improve exercise tolerance and build confidence.
• Management of CTEPH: For patients who develop CTEPH, treatment is complex and may involve specialized medications to lower pulmonary artery pressure, and in some cases, a major surgical procedure called a pulmonary thromboendarterectomy to remove the chronic, organized clots from the arteries.

Blood Clot Caused by COVID-19 vs. One Caused by Prolonged Inactivity

The fundamental difference between a blood clot caused by COVID-19 and one from prolonged inactivity lies in the underlying mechanism; a flight-related clot is primarily a mechanical issue of blood flow, whereas a COVID-19 clot is a systemic, inflammatory disease process.

A clot formed during a long flight is a classic example of venous stasis, where blood in the deep veins of the legs pools and becomes stagnant due to lack of movement. This sluggish flow allows clotting factors to accumulate, leading to the formation of a deep vein thrombosis (DVT).

If a piece of this clot breaks off, it can travel to the lungs, causing a PE. The primary driver is mechanical and localized to the veins. In stark contrast, COVID-19 induces a state of severe systemic inflammation and hypercoagulability. The SARS-CoV-2 virus can directly infect and damage the endothelium (the inner lining of blood vessels), triggering an aggressive inflammatory response and activating the body’s clotting cascade throughout the circulatory system, not just in the legs.

This widespread, inflammation-driven clotting is far more aggressive and can form clots directly within the small vessels of the lungs (immunothrombosis) in addition to causing traditional DVTs. This distinction in pathophysiology explains why COVID-19-associated clots can be more severe and widespread.

• Primary Cause: A flight-related clot is caused by stasis (impaired blood flow from immobility). A COVID-19-related clot is caused by a trifecta of endothelial injury (viral damage to vessel walls), hypercoagulability (an overactive clotting system), and inflammation (the cytokine storm).
• Location of Formation: While both can result in a PE, flight-related clots almost always originate as a DVT in the legs. COVID-19 can cause DVTs but is also associated with thrombosis in unusual locations, including the arteries, brain, and the microvasculature of the lungs themselves.
• Systemic vs. Localized: Immobility creates a localized problem in the deep veins. COVID-19 creates a systemic problem where the entire circulatory system is primed to form clots due to viral attack and the body’s over-the-top immune response, making the risk much higher and less predictable.

Does COVID-19 Vaccination Reduce The Risk of Developing These Blood Clots?

COVID-19 vaccination significantly reduces the risk of developing blood clots from a SARS-CoV-2 infection by preventing severe disease, which is the primary driver of these thrombotic events. The severe inflammatory response, endothelial damage, and hypercoagulable state that lead to pulmonary emboli are hallmarks of moderate to severe COVID-19 illness, often requiring hospitalization.

Vaccination works by training the immune system to recognize and neutralize the virus quickly upon exposure. This prevents the virus from replicating uncontrollably and triggering the widespread, dysregulated immune reaction (the cytokine storm) responsible for systemic inflammation and blood vessel damage. By mitigating the severity of the infection, often reducing it to a mild, cold-like illness or even an asymptomatic case, vaccination effectively removes the conditions necessary for dangerous clots to form.

The risk of developing a PE or other major blood clot is substantially higher in unvaccinated individuals who contract COVID-19 compared to vaccinated individuals. The protective effect of vaccination far outweighs any associated risks, putting the danger of infection-induced clots into clear perspective.

• Mechanism of Protection: Vaccination reduces the risk of severe COVID-19, hospitalization, and ICU admission. Since severe disease is the strongest predictor of developing COVID-19-associated coagulopathy, preventing it is the most effective way to prevent related blood clots.
• Comparative Risk: Studies have consistently shown that the incidence of thrombotic events like DVT and PE is many times higher following a SARS-CoV-2 infection than in the weeks following vaccination. For example, the risk of cerebral venous sinus thrombosis (a rare brain clot) is estimated to be 8-10 times higher after infection than after receiving an mRNA vaccine.
• Clarifying Vaccine-Associated Risks: While extremely rare cases of clotting disorders (like VITT with certain viral vector vaccines) were identified early on, these events are exceedingly uncommon. The danger posed by the virus itself, with its propensity to cause widespread, life-threatening clots, is a far greater and more common threat to an individual’s health.

FAQs

1. What are the pulmonary complications of COVID-19?

COVID-19 can affect the lungs in several ways, ranging from mild irritation to serious, long-term damage. Common complications include pneumonia, where the air sacs fill with fluid, and acute respiratory distress syndrome (ARDS), a severe condition that makes breathing extremely difficult.

Another major concern is blood clot formation, which can lead to pulmonary embolism. Some individuals also experience long-term inflammation and scarring (fibrosis), which can reduce lung function even after recovery. These complications vary depending on the severity of the infection and the individual’s overall health.

2. How long after COVID are you susceptible to blood clots?

The risk of blood clots can remain elevated for several weeks to months after COVID-19 infection. Research suggests that the highest risk is within the first 2 to 6 weeks, but in some cases, it may persist longer, especially in people who had severe illness or were hospitalized. This lingering risk is one reason why symptoms like sudden shortness of breath or chest pain should never be ignored, even after recovery.

3. Does COVID permanently damage the lungs?

Not always, but in some cases, COVID-19 can cause long-term or permanent lung damage. Severe infections may lead to scarring of lung tissue, known as fibrosis, which can affect breathing capacity. However, many people recover fully, especially those with mild to moderate illness. The outcome often depends on how severe the infection was and how quickly treatment was received.

4. How long does it take for lungs to heal from COVID?

Recovery time varies widely. For mild cases, lung function may return to normal within a few weeks. For more severe infections, healing can take several months, and some symptoms like shortness of breath or fatigue may linger. Rehabilitation, breathing exercises, and proper medical follow-up can support recovery and improve lung function over time.

Conclusion

COVID-19 changed how people think about respiratory illness, but its impact goes beyond the lungs alone. The connection between COVID-19 and pulmonary embolism reveals a hidden layer of risk, one that can develop quietly, even after the initial infection has passed. Understanding this link is essential.

Blood clots are not always immediate, and symptoms may appear when you least expect them. That is why ongoing awareness matters, especially during recovery. Paying attention to your body, recognizing warning signs, and seeking timely care can make a critical difference.

The reassuring part is that knowledge gives you control. When you understand how COVID-19 affects both the lungs and the bloodstream, you are better prepared to protect your health and respond early if something feels wrong.

References:

• National Library of Medicine – Long COVID and Wavering Incidence of Pulmonary Embolism: A Systematic Review
• Science Direct – Long-term outcomes of COVID-19-associated pulmonary embolism: A French single-center retrospective study with one-year follow-up
• Cleveland Clinic – COVID-19 Lung Damage
• American Lung Association – COVID-19 Recovery
• National Library of Medicine – Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States
• CDC  – People with Certain Medical Conditions and COVID-19 Risk Factors
• University of Nebraska Medical Center – Long COVID scientists try to unravel blood clot mystery

Disclaimer

This article is intended for informational and educational purposes only. We are not medical professionals, and this content does not replace professional medical advice, diagnosis, or treatment.

The goal is to provide accurate, evidence-based information to raise awareness of the link between Covid-19 and pulmonary embolism. If you are experiencing persistent, severe, or concerning symptoms, you should seek guidance from a qualified healthcare provider.

Read more: Pulmonary Embolism (PE): Causes, Symptoms, Diagnosis, and Treatment